Epidemiology, hospitalization and migration of patients with IBD under specialized care in the Czech Republic
Jiří Jarkovský Orcid.org 1,2, Klára Benešová1,2, Karel Hejduk1, Ladislav Dušek Orcid.org 3,4, Milan Lukáš Orcid.org 5
1 Institut biostatistiky a analýz, LF MU, Brno
2 Ústav zdravotnických informací a statistiky České republiky, Praha
3 Ústav zdravotnických informací a statistiky ČR, Praha
4 Institut biostatistiky a analýz LF MU, Brno
5 IBD clinical and research centre ISCARE a.s., Prague, Czech Republic
Aim: To analyse data obtained by the Institute of Health Information and Statistics of the Czech Republic (IHIS CR) from patients with Crohn’s disease (CD) and ulcerative colitis (UC) under specialized care in terms of incidence, prevalence, hospitalization, mortality and patient migration. Patients and Methods: We analysed data from 19,797,081 hospitalization records, a database of death records, annual gastroenterology reports and the Czech National Cancer Registry related to the diagnosis of CD and UC in 2007–2015 obtained by the IHIS CR. Results: The incidence of CD and UC sharply increased over this period and reached 22.7 and 27.9 cases per 100,000 people, respectively. A total of 46,608 patients were followed up in the Czech Republic. The mortality rate of CD patients was relatively low and remained stable over time at around 0.4%. By contrast, the mortality rate of UC patients was 6-fold higher and was particularly high in those who underwent surgery. Surprisingly, only 60 UC patients were operated on annually. As expected, the most important healthcare sites dedicated to the management of inflammatory bowel disease (IBD) are located in the largest cities of the Czech Republic, including teaching and non-teaching hospitals in Prague, Brno, Ostrava and Hradec Kralove. Conclusions: This study analysed data obtained by the IHIS CR. The prevalence of IBD was higher than expected and its incidence increased recent years. The mortality rate of UC patients was 6-fold higher than that of CD patients.
KeywordsCrohn’s disease, epidemiology, hospitalization, mortality, ulcerative colitis
1. Feuerstein JD, Cheiftetz AS. Ulcerative colitis: epidemiology, diagnosis and management. Mayo Clinic Proc 2014; 89 (11): 1553–1563. doi: 10.1016/j.mayocp.2014.07.002.
2. Burisch J, Vegh Z, Pedersen N et al. Health care and patients education in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study. J Crohns Colitis 2014; 8 (8): 811–818. doi: 10.1016/j.crohns.2013.12.023.
3. Vavricka S, Spigaglia SM, Rogler G et al. Systemic evaluation of risk factors diag-nostic delay in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18 (3): 496–505. doi: 10.1002/ibd.21719.
4. Annese V, Duricova D, Gower-Rousseau C et al. Impact of new treatments on hospitalisation, surgery, infection and mortality in IBD: a focus paper by the epidemiology committee of ECCO. J Crohn Colitis 2016; 10 (2): 216–225. doi: 10.1093/ecco-jcc/jjv190.
5. Burisch J, Pedersen N, Cučkovič-Čavka S et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2014; 63: 588–597. doi: 10.1136/gutjnl-2013-304636.
6. Bortlík M. Vývoj léčby idiopatických střevních zánětů v posledních 20 letech. Gastroent Hepatol 2015; 69 (4): 341–350.
7. Romanko I. Current position of eHealth care in management of IBD patients. Gastroent Hepatol 2017; 71 (4): 315–322. doi: 10.14735/amgh2017315
8. De Jong M, Van Der Meulen, Romberg-Camps M et al. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel diseasse: a pragmatic randomized multicenter trial with myIBDcoach. Present-ed at: DDW 2017, Chicago, May 6–9 2017. Abstract OP017.
9. Mináriková P, Minárik M, Zavoral M. Inflammatory bowel disease and gastrointestinal malignacies: risks, incidence and management. Gastroent Hepatol 2017; 71 (5): 388–393. doi: 10.14735/amgh2017 388.